Lobeline, a potential pharmacotherapy for drug addiction, binds to μ opioid receptors and diminishes the effects of opioid receptor agonists

Drug and Alcohol Dependence

Volumn 89, Issue 2-3, 2007, Pages 282-291

  Miller, Dennis K ^a   Lever, John R ^b,c   Rodvelt, Kelli R ^a   Baskett, James A ^b   Will, Matthew J ^a   Kracke, George R ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

DAMGO; Dopamine; Dopamine transporter; Lobeline morphine; Opioid receptor; Striatum

Indexed keywords

DOPAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; LOBELINE; MECAMYLAMINE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NICOTINE; TRITIUM;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; GUINEA PIG; IC 50; MEMBRANE STEADY POTENTIAL; NONHUMAN; OOCYTE; OPIATE ADDICTION; POTASSIUM CURRENT; PRIORITY JOURNAL; STRIATE CORTEX; XENOPUS;

ANALGESICS, OPIOID; ANIMALS; BINDING, COMPETITIVE; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GUINEA PIGS; LOBELINE; MECAMYLAMINE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NICOTINE; OOCYTES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; XENOPUS LAEVIS;

CAVIA; RATTUS;

EID: 34248593694     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.02.003     Document Type: Article

References (41)

1. Aceto M.D., Bowman E.R., Harris L.S., Kipps B.R., and May E.L. Dependence studies of new compounds in the rhesus monkey, rat and mouse. In: Harris L.S. (Ed). Problems of Drug Dependence 2001: Proceedings of the 63rd Annual Scientific Meeting (2001), National Institute on Drug Abuse Research Monograph Series, Washington, DC 157-209
2. Blednov Y.A., Stoffel M., Alva H., and Harris R.A. A pervasive mechanism for analgesia: activation of GIRK2 channels. Proc. Natl. Acad. Sci. U.S.A. 100 1 (2003) 277-282
3. Cheng Y.-C., and Prusoff W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition of an enzymatic reaction. Biochem. Pharmacol. 22 23 (1973) 3099-3108
4. Childers S.R. Opioid receptor-coupled second messenger systems. Life Sci. 48 21 (1991) 1991-2003
5. Cunningham C.S., Polston J.E., Jany J.R., Segert I.L., and Miller D.K. Interaction of lobeline and nicotinic receptor ligands with the discriminative stimulus properties of cocaine and amphetamine. Drug Alcohol Depend. 84 3 (2006) 211-222
6. Damaj M.I., Patrick G.S., Creasy K.R., and Martin B.R. Pharmacology of lobeline, a nicotinic receptor ligand. J. Pharmacol. Exp. Ther. 282 1 (1997) 410-419
7. Davison G.C., and Rosen R.C. Lobeline and reduction of cigarette smoking. Psychol. Rep. 31 2 (1972) 443-456
8. Dwoskin L.P., and Crooks P.A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63 2 (2002) 89-98
9. Enrico P., Mura M.A., Esposito G., Serra P., Migheli R., De Natale G., Desole M.S., Miele M., and Miele E. Effect of naloxone on morphine-induced changes in striatal dopamine metabolism and glutamate, ascorbic acid and uric acid release in freely moving rats. Brain Res. 797 1 (1998) 94-102
10. Eyerman D.J., and Yamamoto B.K. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J. Pharmacol. Exp. Ther. 312 1 (2005) 160-169
11. Fadda P., Scherma M., Fresu A., Collu M., and Fratta W. Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice. Synapse 56 1 (2005) 29-38
12. Flammia D., Dukat M., Damaj M.I., Martin B., and Glennon R.A. Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J. Med. Chem. 42 18 (1999) 3726-3731
13. 3H]norepinephrine from fetal rat locus coeruleus cells in culture. J. Neurochem. 70 2 (1998) 663-670
14. Harrod S.B., Dwoskin L.P., Crooks P.A., Klebaur J.E., and Bardo M.T. Lobeline attenuates d-methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 298 1 (2001) 172-179
15. Herz A. Opioid reward mechanisms: a key role in drug abuse?. Can. J. Physiol. Pharmacol. 76 3 (1998) 252-258
16. Heyl D.L., and Mosberg H.I. Substitution on the Phe3 aromatic ring in cyclic delta opioid receptor-selective dermorphin/deltorphin tetrapeptide analogues: electronic and lipophilic requirements for receptor affinity. J. Med. Chem. 35 9 (1992) 1535-1541
17. Hunt P., Kannengiesser M.-H., and Raynaud J.-P. Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J. Pharm. Pharmacol. 26 (1974) 370-371
18. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction. 3rd Ed. (1997), Lippincott-Raven, Philadelphia
19. Lever J.R., Gustafson J.L., Xu R., Allmon R.L., and Lever S.Z. Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 59 6 (2006) 350-358
20. Ling W., Rawson R.A., and Compton M.A. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J. Psychoactive Drugs 26 2 (1994) 119-128
21. Melis M., Gessa G.L., and Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog. Neuropsychopharmacol. Biol. Psychiat. 24 6 (2000) 993-1006
22. Miller A.D., and Blaha C.D. Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat. Eur. J. Neurosci. 21 7 (2005) 1837-1846
23. Miller D.K. Review of research on lobeline, a potential pharmacotherapy for methamphetamine abuse. In: Toolaney G.R. (Ed). New Research on Methamphetamine Abuse (2006), Nova Science Publishers, Hauppauge, NY
24. + efflux from thalamic synaptosomes. Neuropharmacology 39 13 (2000) 2654-2662
25. Miller D.K., Crooks P.A., Teng L., Witkin J.M., Munzar P., Goldberg S.R., Acri J.B., and Dwoskin L.P. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J. Pharmacol. Exp. Ther. 296 3 (2001) 1023-1034
26. * nAChRs. J. Pharmacol. Exp. Ther. 310 (2004) 1035-1045
27. Nunn-Thompson C.L., and Simon P.A. Pharmacotherapy for smoking cessation. Clin. Pharm. 8 10 (1989) 710-720
28. Palmer R.B., Upthagrove A.L., and Nelson W.L. (E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays. J. Med. Chem. 40 5 (1997) 749-753
29. Piepponen T.P., Mikkola J.A., Ruotsalainen M., Jonker D., and Ahtee L. Characterization of the decrease of extracellular striatal dopamine induced by intrastriatal morphine administration. Br. J. Pharmacol. 127 1 (1999) 268-274
30. Pierce R.C., and Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci. Biobehav. Rev. 30 (2006) 215-238
31. Quick M.W., and Lester H.A. Methods of expression of excitability proteins in Xenopus oocytes. In: Narahashi T. (Ed). Methods in Neuroscience-Ion Channels of Excitable Cells (1994), Academic Press, San Diego 261-279
32. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., and Reisine T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 45 2 (1994) 330-334
33. Rouge-Pont F., Usiello A., Benoit-Marand M., Gonon F., Piazza P.V., and Borrelli E. Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J. Neurosci. 22 8 (2002) 3293-3301
34. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanism of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75 (2005) 406-433
35. Tatsuta T., Kitanaka N., Kitanaka J., Morita Y., and Takemura M. Lobeline attenuates methamphetamine-induced stereotypy in adolescent mice. Neurochem. Res. 31 (2006) 1359-1369
36. 3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280 3 (1997) 1432-1444
37. 3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 71 1 (1998) 258-265
38. Vocci F., and Ling W. Medications development: successes and challenges. Pharmacol. Ther. 108 (2005) 94-108
39. Westerink B.H., and Kikkert R.J. Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J. Neurochem. 46 4 (1986) 1145-1152
40. Westfall T.C., Grant H., and Perry H. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen. Pharmacol. 14 3 (1983) 321-325
41. Wilhelm C.J., Johnson R.A., Lysko P.G., Eshleman A.J., and Janowsky A. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. J. Pharmacol. Exp. Ther. 310 3 (2004) 1142-1151